Based on histopathological, genetic, and epigenetic analyses, tumors were diagnosed as: 10 DIG (33.3%), six IHG (20%), three gangliogliomas (10%), two PXA (6.7%), two supratentorial ependymomas, ZFTA‐fusion positive (6.7%), two supratentorial ependymomas, YAP1‐fusion positive (6.7%), two pilocytic astrocytomas (PA) (6.7%), two CNS embryonal tumors, with PLAGL2 amplification (6.7%), and one diffuse low‐grade glioma (DLGG), MAPK pathway‐altered (BRAF‐mutant, 3.3%), (Figures 1 and 2). This evidence concerns the gene PLAGL2 and ependymoma.